Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics

Type of publication: Care, Guidelines, Treatment guidelines
Disease: Motor neuron disease, Spinal muscular atrophy

Authors:

Richard S.Finkel, Eugenio Mercuri, Oscar H.Meyer, Anita K.Simonds, Mary K.Schroth, Robert J.Graham, Janbernd Kirschner, Susan T.Iannaccone, Thomas O.Crawford, Simon Woods, Francesco Muntoni, Brunhilde Wirth, Jacqueline Montes, Marion Main, Elena S. Mazzone, Michael Vitale, Brian Snyder, Susana Quijano-Roy, Thomas Sejersen


Abstract

This is the second half of a two-part document updating the standard of care recommendations for spinal muscular atrophy published in 2007. This part includes updated recommendations on pulmonary management and acute care issues, and topics that have emerged in the last few years such as other organ involvement in the severe forms of spinal muscular atrophy and the role of medications. Ethical issues and the choice of palliative versus supportive care are also addressed. These recommendations are becoming increasingly relevant given recent clinical trials and the prospect that commercially available therapies will likely change the survival and natural history of this disease.


Published: 1 March 2018
Journal: Neuromuscular Disorders, volume 28, issue 3, pages 197-207

doi.org/10.1016/j.nmd.2017.11.004

This publication is recommended by the Motor Neuron Diseases Working Group group.

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern